Impact BioMedical Inc. filed a current report on November 18, 2026, disclosing the November 17, 2026 completion of its Business Combination with Zoar Limited and the concurrent withdrawal of its common stock from NYSE American.

Key Highlights

  • Merger closed November 17, 2026: Merger Sub merged with and into Impact BioMedical, with Impact continuing as the surviving corporation and a wholly-owned subsidiary of PubCo (Zoar Limited).
  • Reverse stock split applied: Company Common Stock underwent a 1-for-12.62 reverse stock split prior to the Effective Time, after which each share converted into one PubCo Ordinary Share.
  • Impact stockholders received 8,640,000 PubCo Ordinary Shares, representing approximately 4.80% of total issued and outstanding PubCo Ordinary Shares at closing.
  • Zoar Shareholder received 167,976,000 PubCo Ordinary Shares, representing approximately 94.02% of total issued and outstanding PubCo Ordinary Shares at closing.
  • IBO trading suspended: The Company requested NYSE American suspend trading of Company Common Stock prior to the open of trading on November 18, 2026, and withdraw its listing.
  • New ticker expected: PubCo Ordinary Shares are expected to begin trading on NYSE American under the symbol "ZOAR" on November 18, 2026.
  • Delisting notice filed: NYSE American was asked to file a notification of removal from listing, with the delisting becoming effective ten days after that filing.

Business Combination Closes, Ending Impact BioMedical's Independent Listing

According to the filing, the Business Combination was carried out under a Merger and Share Exchange Agreement originally dated June 21, 2025, and subsequently amended twice, with the most recent amendment dated August 13, 2026. The stockholders of Impact BioMedical Inc., a Nevada corporation focused on biomedical technologies, approved the transaction at a special meeting held on November 13, 2026. The Articles of Merger were filed with the Secretary of State of Nevada on November 17, 2026, establishing the Effective Time.

At the Effective Time, all outstanding Impact Options and Impact Warrants that were not vested or exercisable became fully vested immediately prior to closing, the filing disclosed. In-the-Money Impact Options and Warrants were cancelled and their holders became entitled to receive shares of Company Common Stock, which were then converted into Merger Consideration. Options and warrants with exercise prices at or above the Impact Closing Price were cancelled for no consideration. In addition to the shares issued to the Zoar Shareholder, the filing states PubCo issued 22,000 Ordinary Shares to Frank D. Heuszel, the Company's Chief Executive Officer, as Compensation Shares, 228,000 Ordinary Shares to DSS, Inc., and 1,800,000 Ordinary Shares to BMI Capital International LLC, representing approximately 1.00% of total issued and outstanding PubCo Ordinary Shares at closing.

The PubCo Ordinary Shares issued in the Business Combination were registered under PubCo's Registration Statement on Form F-4 (File No. 333-298856), which the SEC declared effective on October 23, 2026, according to the filing. Following the delisting of Company Common Stock, Impact BioMedical also stated its intention to file a Form 15 certification with the SEC to deregister Company Common Stock under Section 12(g) of the Exchange Act and suspend its reporting obligations under Sections 13 and 15(d) of the Exchange Act.

What Was Disclosed

Impact BioMedical Inc. (NYSE American:IBO) reported the November 17, 2026 closing of its merger into Zoar Limited, a 1-for-12.62 reverse stock split, conversion of IBO shares into PubCo Ordinary Shares, and the initiation of steps to delist and deregister Company Common Stock from NYSE American.